Introduction
============

17β-Estradiol (E2) is a primary sex hormone in human beings that is essential for the development and maintenance of female reproductive organs.[@b1-ott-10-3421] However, it also has important effects on many other tissues, such as bone,[@b2-ott-10-3421] liver,[@b3-ott-10-3421] and brain.[@b4-ott-10-3421] E2 is mainly produced by the granulosa cells of ovaries in women,[@b5-ott-10-3421] but it can also be produced by the testes in men.[@b6-ott-10-3421],[@b7-ott-10-3421] E2 has been used for treating menopausal syndrome[@b8-ott-10-3421] and preventing osteoporosis in postmenopausal women.[@b9-ott-10-3421] In addition, it has been reported that older men with total E2 deficiency are more likely to be osteoporotic.[@b10-ott-10-3421] E2 has also been implicated in cancer progression.[@b11-ott-10-3421],[@b12-ott-10-3421] Recently, Tchafa et al[@b13-ott-10-3421] have found that E2 promotes the cellular invasion and proliferation of breast cancer cells. Gunter et al[@b12-ott-10-3421] have reported that endogenous E2 levels are positively associated with the risk of colorectal cancer.

Osteosarcoma is the most common primary malignancy of bone and exhibits a high risk of metastasis and poor prognosis.[@b14-ott-10-3421],[@b15-ott-10-3421] Although E2 is known to play a critical role in osteosarcoma, its effects in this disease are controversial. E2 can inhibit purine metabolic and biosynthetic pathways in human osteosarcoma cells to achieve an antagonistic effect on cell proliferation.[@b16-ott-10-3421] Previous studies have also shown that E2 protects against cell death in estrogen receptor-α and -β-expressing human U2OS osteosarcoma cells.[@b17-ott-10-3421],[@b18-ott-10-3421] Furthermore, 2-methoxyestradiol, a mammalian metabolite of E2, has been reported to induce cell cycle arrest and osteosarcoma cell apoptosis.[@b19-ott-10-3421] Therefore, defining the molecular mechanism(s) of E2 actions in osteosarcoma cells is necessary. In the present study, high-throughput RNA sequencing (RNA-seq) and bioinformatics methods were used to identify changes in the gene expression profile that are associated with E2 treatment of U2OS osteosarcoma cells.

Materials and methods
=====================

Cell lines and culture conditions
---------------------------------

Human U2OS osteosarcoma cells were purchased from Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, People's Republic of China). Cells were maintained in phenol red-free Roswell Park Memorial Institute (RPMI)-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin--streptomycin (Thermo Fisher Scientific, Waltham, MA, USA) in a humidified atmosphere of 95% air and 5% CO~2~ at 37°C. Before beginning treatments, cells were washed twice with phosphate-buffered saline (PBS) to remove residual serum and were grown in serum-free RPMI-1640 medium for 24 h. Subsequently, E2 (15 μmol/L, dissolved in dimethyl sulfoxide \[DMSO\]) was added to the medium, and an equal volume of DMSO was added to the control U2OS cell medium. Two U2OS cell samples (14710C-3 and 14710C-4) treated with E2 and two untreated control U2OS samples (14710C-1 and 14710C-2) were subjected to RNA-seq.

RNA extraction and sequencing
-----------------------------

After an incubation period of 48 h, cells were washed twice with PBS and harvested. Total RNA was isolated from cultured cells using TRIzol^®^ Reagent (Thermo Fisher Scientific) according to the manufacturer's instruction. RNA quality and quantity were assessed by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). cDNA libraries were constructed using an NEBNext^®^ Ultra™ RNA Library Prep Kit (Illumina, Shanghai, People's Republic of China) following the manufacturer's instruction. Subsequently, libraries were sequenced on Illumina HiSeq 2000 at Beijing Berry Genomics Co., Ltd. Sequenced reads were generated by base calling using the Illumina standard pipeline. Paired-end RNA-seq data were generated with a read length of 100 bp. The raw sequencing data have been uploaded to the National Center for Biotechnology Information database under the BioProject accession no SRP101761.

Alignment of sequenced reads
----------------------------

Raw reads were first filtered to obtain clean reads using FASTX-Toolkit (<http://hannonlab.cshl.edu/fastx_toolkit/>).[@b20-ott-10-3421] High-quality reads were mapped to the human reference genome hg19 using TopHat (version 2.0.12) software[@b21-ott-10-3421] with default parameters. Alignment was independently performed for reads from each sample, and reads mapping to more than three genomic sites were discarded.

Differentially expressed genes (DEGs) screening
-----------------------------------------------

Based on the value of reads per kilobase per million mapped reads, gene expression levels were determined using Cufflinks software (version 2.21).[@b22-ott-10-3421] Subsequently, the Cuffdiff program[@b23-ott-10-3421] of Cufflinks was used to identify DEGs. Only the genes with \|log(fold change)\| \>1 and *P*\<0.01 were considered as DEGs.

Gene ontology (GO) enrichment analysis
--------------------------------------

Database for Annotation, Visualization and Integrated Discovery (DAVID)[@b24-ott-10-3421] is an online tool used for functional annotation of genes. A GO functional enrichment analysis of DEGs was performed using the DAVID. *P*\<0.05 was chosen as the cutoff criterion.

Construction of protein--protein interaction (PPI) network
----------------------------------------------------------

The Human Protein Reference Database (<http://www.hprd.org/>)[@b25-ott-10-3421] is a database for experimentally derived information about the human proteome, including that on PPIs, post-translational modifications, and tissue expression. DEG-encoding proteins were mapped to the Human Protein Reference Database to search for interaction relationships. The PPI network was visualized using Cytoscape.[@b26-ott-10-3421] Finally, the hub nodes with a high degree of connectivity[@b27-ott-10-3421] in the PPI network were also identified.

*NFKB1* expression levels using quantitative real-time polymerase chain reaction (qRT-PCR)
------------------------------------------------------------------------------------------

To confirm RNA-seq results, *NFKB1* and *AKT1* expression levels were detected using qRT-PCR. Total RNA was extracted using TRIzol Reagent following the manufacturer's instructions (TaKaRa, Dalian, People's Republic of China). Subsequently, the first-strand cDNA was prepared from total lens RNA using a TaKaRa PrimeScript II First Strand cDNA Synthesis Kit (RR036A-1; TaKaRa) according to the manufacturer's instructions. Glyceraldehyde-3-phosphate dehydrogenase was used as a control. The primers used for *NFKB1*, *AKT1*, and glyceraldehyde-3-phosphate dehydrogenase were based on the rat sequences: 5′-AACAGCAGATGGCCCATA CC-3′ (forward), 5′-AACCTTTGCTGGTCCCACAT-3′ (reverse); 5′-GCCTGTCAGCTGGTGCAT-3′ (forward), 5′-CCGCCAGGTCTTGATGTACT-3′ (reverse); and 5′-CA GTGCCAGCCTCGTCTCAT-3′ (forward), 5′-AGGGGCCATCCACAGTCTTC-3′ (reverse), respectively.

Statistical analysis
--------------------

Differences between the two treatment groups were analyzed using unpaired Student's *t*-test. Data analysis was completed using SPSS 22.0 (IBM Corporation, Armonk, NY, USA). *P*\<0.05 was considered to indicate statistically significant difference.

Results
=======

Sequence alignment
------------------

The results of TopHat alignment of clean reads with the human reference genome are shown in [Table 1](#t1-ott-10-3421){ref-type="table"}. In total, 9,485,360 (68.63%) and 7,843,445 (65.76%) of clean reads were mapped to the human reference genome for the two E2-treated U2OS cell samples; 8,129,145 (69.71%) and 8,531,536 (69.07%) cleans reads were mapped for the two control samples.

DEGs and GO enrichment analysis
-------------------------------

In total, 220 genes, including 128 upregulated and 92 downregulated genes, were identified as being significantly differently expressed between E2-treated U2OS osteosarcoma cells and the controls. According to the GO enrichment analysis, the top five GO terms of upregulated DEGs *NFKB1*, *ATF7IP*, *HDAC5*, *MEN1*, and *EPC1* were significantly related to the regulation of gene expression and transcription ([Table 2](#t2-ott-10-3421){ref-type="table"}). Meanwhile, the top five GO terms of downregulated DEGs included Wnt receptor signaling through β-catenin involving *RARG*, *TBL1X*, and *TCF7L2*; axonogenesis involving *ALCAM*, *NRP1*, and *SLC26A6*; and cell cycle processes involving *AKT1*, *DSN1*, and *POLD1* ([Table 3](#t3-ott-10-3421){ref-type="table"}).

Construction of the PPI network
-------------------------------

In total, 1,185 nodes, including 91 upregulated DEGs, 55 downregulated DEGs, and 1,064 non-DEGs, were present in the PPI network ([Figure 1](#f1-ott-10-3421){ref-type="fig"}). The top five DEGs with the highest degree of connectivity in the network were AKT1 (117), NFKB1 (72), ATF7IP (64), NCOA3 (45), and HDAC5 (36).

Differences in *NFKB1* and *AKT1* expression levels
---------------------------------------------------

As shown in [Figure 2A](#f2-ott-10-3421){ref-type="fig"}, *NFKB1* expression levels significantly increased when U2OS osteosarcoma cells were treated with E2 (*P*=0.002), which confirmed the reliability of the bioinformatics method. Although *AKT1* expression levels were increased when U2OS osteosarcoma cells were treated with E2, they were not significantly different (*P*\>0.05; [Figure 2B](#f2-ott-10-3421){ref-type="fig"}).

Discussion
==========

In the current study, RNA-seq was used to explore changes in the gene expression profile that are associated with E2 treatment of U2OS osteosarcoma cells. We found that E2 treatment induced the upregulation of genes related to the regulation of gene expression and transcription (eg, *NFKB1*, *ATF7IP*, and *HDAC5*) and downregulation of those involved in Wnt receptor signaling through β-catenin and morphogenesis (eg, *TCF7L2*, *ALCAM*, *NRP1*, *SLC26A6*, and *AKT*).

Our results demonstrated that *NFKB1* was mainly enriched in the regulation of gene expression and transcription. *NFKB1* belongs to the *NF-κB* family, which contains a group of proteins involved in carcinogenesis, immune response, cell adhesion, proliferation, angiogenesis, and apoptosis.[@b28-ott-10-3421] *NF-κB* is a transcription factor that participates in the regulation of viral and cellular genes.[@b29-ott-10-3421] Constitutive *NF-κB* activation has been observed in 67% of colorectal cancer cell lines and promoted tumor growth.[@b30-ott-10-3421] *NFKB2*, another member of the *NF-κB* family, can stimulate cell proliferation in U2OS osteosarcoma cells.[@b31-ott-10-3421] Furthermore, several studies have shown the relationship between *NFKB1* and tumors. For example, a functional insertion/deletion polymorphism in the promoter region of *NFKB1* increases the risk of nasopharyngeal carcinoma.[@b32-ott-10-3421] Riemann et al[@b33-ott-10-3421] discovered that the *NFKB1* promoter polymorphism was a useful molecular marker for the risk of recurrence in superficial bladder cancer. However, although most studies have analyzed the correlation of the *NFKB1* promoter polymorphism with tumors,[@b31-ott-10-3421],[@b34-ott-10-3421] those analyzing the effects of *NFKB1* expression in osteosarcoma are limited. Thus, further experiments are needed to explore whether *NFKB1* expression has any impact on osteosarcoma progression.

We also found that E2 treatment may repress the expression of genes, such as *RARG*, *TBL1X*, and *TCF7L2*, involved in Wnt receptor signaling through β-catenin in U2OS osteosarcoma cells. The activation of Wnt signaling and the accumulation of β-catenin have been reported in many carcinomas,[@b35-ott-10-3421],[@b36-ott-10-3421] including osteosarcoma.[@b37-ott-10-3421] *TCF7L2* encodes the transcription factor TCF-4, which can be activated by dephosphorylated β-catenin via binding to a conserved N-terminal region in the nucleus, thereby initiating the expression of target genes, including the proto-oncogenes *c-jun* and *fra-1*.[@b38-ott-10-3421] Thus, E2 treatment may have an unfavorable effect on U2OS osteosarcoma cells.

Among the other downregulated DEGs, *AKT1* was observed to have the highest degree in the PPI network. *AKT*, also known as protein kinase B (PKB; a serine/threonine kinase), is one of the most critical and versatile protein kinases involved in the mechanism of human physiology and disease.[@b39-ott-10-3421],[@b40-ott-10-3421] The activation of AKT pathways plays a central role in tumor metastasis.[@b41-ott-10-3421] Furthermore, Fukaya et al[@b42-ott-10-3421] have demonstrated the important role of AKT signaling in the pulmonary metastasis of osteosarcoma. The AKT family has three members: AKT1/PKBα, AKT2/PKBβ, and AKT3/PKBγ. *AKT1* and *AKT2* have been reported to be ubiquitously and similarly expressed in various tissues.[@b43-ott-10-3421] Recently, Zhu et al[@b44-ott-10-3421] have reported that elevated *AKT2* expression is associated with poor outcomes in patients with osteosarcomas.

Here, *AKT1* was enriched in the cell cycle process, which was closely related to tumor progression. A study by Ju et al[@b45-ott-10-3421] has revealed that *AKT1* governed breast cancer progression in mice, whereas another study has indicated that *AKT1* amplification regulates cisplatin (a chemotherapeutic agent) resistance in human lung cancer.[@b46-ott-10-3421] Collectively, these reports have demonstrated that *AKT1* might be closely involved in osteosarcoma metastasis. In the current study, we predicted that *AKT1* expression was downregulated. According to qRT-PCR results, although *AKT1* expression levels were increased when U2OS osteosarcoma cells were treated with E2, they were not significantly different. However, the effect of *AKT* expression on U2OS osteosarcoma cells is controversial. For example, Nielsen-Preiss et al[@b47-ott-10-3421] have reported that the downregulation of *AKT* expression enhances osteosarcoma cell proliferation, whereas Díaz-Montero et al[@b48-ott-10-3421] have found that *AKT* expression is upregulated in anoikis-resistant human osteosarcoma SAOSar cells. Therefore, we speculated that E2 is involved in osteosarcoma metastasis, but the modulating mechanism is still unclear.

*ALCAM* was another gene downregulated by E2 treatment in U2OS osteosarcoma cells, which was speculated to function in axonogenesis, cell morphogenesis involved in neuron differentiation, cell cycle processes, and neuron projection morphogenesis. *ALCAM* encodes the CD166 antigen, which is a 100--105 kDa type-I transmembrane glycoprotein of the immunoglobulin protein superfamily. Similar to *CD29*, *CD44*, *CD73*, *CD90*, *CD105*, and *CD106*, it is known as a marker of the mesenchymal stem cell phenotype.[@b49-ott-10-3421],[@b50-ott-10-3421] Its overexpression has also been reported in colorectal carcinoma[@b51-ott-10-3421] and has been demonstrated to be associated with a poor prognosis of several tumors.[@b51-ott-10-3421]--[@b53-ott-10-3421] Federman et al have reported that *CD166* is highly expressed in the osteosarcoma cell lines HOS, KHOS, KHOS240s, and SJSA, but its expression status is not observed in U2OS osteosarcoma cells.[@b54-ott-10-3421] They further proposed that this gene is a potential candidate for the targeted therapy of osteosarcoma. Our findings suggested that E2 treatment decreases *ALCAM* expression in U2OS osteosarcoma cells, thereby playing an inhibitory role against osteosarcoma.

Taken together, we found that E2 treatment may mainly upregulate the expression of genes, such as *NFKB1*, *ATF7IP*, and *HDAC5*, related to the regulation of gene expression and transcription and downregulate that of genes involved in Wnt receptor signaling through β-catenin and morphogenesis (eg, *TCF7L2*, *ALCAM*, *NRP1*, *SLC26A6*, and *AKT*) in U2OS osteosarcoma cells. Thus, we proposed that E2 has an unfavorable effect against U2OS osteosarcoma cells. However, given that our findings were partly obtained using bioinformatics tools, they need to be further validated.
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###### 

Summary of clean reads alignment to the reference genome

  Sample title   Treatment   Clean reads   Mapped reads   Map ratio (%)
  -------------- ----------- ------------- -------------- ---------------
  14710C-1       Control     11660638      8129145        69.71
  14710C-2       Control     12351701      8531536        69.07
  14710C-3       E2          13820514      9485360        68.63
  14710C-4       E2          11927581      7843445        65.76

**Abbreviation:** E2, estradiol.

###### 

The top five GO terms of upregulated DEGs

  Category   Term         Description                                                            *P*-value   Genes
  ---------- ------------ ---------------------------------------------------------------------- ----------- ---------------------------------
  BP         GO:0010628   Positive regulation of gene expression                                 0.002272    *NFKB1*, *ATF7IP*, *HDAC5*, etc
  BP         GO:0010629   Negative regulation of gene expression                                 0.002581    *NFKB1*, *ATF7IP*, *HDAC5*, etc
  BP         GO:0016568   Chromatin modification                                                 0.002959    *HDAC5*, *MEN1*, *EPC1*, etc
  BP         GO:0045944   Positive regulation of transcription from RNA polymerase II promoter   0.004248    *NFKB1*, *HDAC5*, *MEN1*, etc
  BP         GO:0016481   Negative regulation of transcription                                   0.004572    *NFKB1*, *ATF7IP*, *HDAC5*, etc

**Abbreviations:** BP, biological process; GO, gene ontology; DEGs, differentially expressed genes.

###### 

The top five GO terms of downregulated DEGs

  Category   Term         Description                                             *P*-value   Genes
  ---------- ------------ ------------------------------------------------------- ----------- ---------------------------------
  BP         GO:0060070   Wnt receptor signaling pathway through β-catenin        0.002951    *RARG*, *TBL1X*, *TCF7L2*
  BP         GO:0007409   Axonogenesis                                            0.01382     *ALCAM*, *NRP1*, *SLC26A6*, etc
  BP         GO:0048667   Cell morphogenesis involved in neuron differentiation   0.01801     *ALCAM*, *NRP1*, *SLC26A6*, etc
  BP         GO:0022402   Cell cycle process                                      0.01832     *AKT1*, *DSN1*, *POLD1*, etc
  BP         GO:0048812   Neuron projection morphogenesis                         0.01916     *ALCAM*, *NRP1*, *SLC26A6*, etc

**Abbreviations:** BP, biological process; GO, gene ontology; DEGs, differentially expressed genes.
